Results from Phase 1b Studies for C3 Inhibitor

Posted on July 12, 2018

This is the sub cutaneous daily injection which inhibits the C3 part of the complement system (rather than C5) and is promising for those who still need blood transfusions whilst on Soliris

“It was initially very encouraging to see the significant improvements in these significantly anemic patients when APL-2 was added to Soliri,” commented Anita Hill, lead consultant for the National PNH Service at the Leeds Teaching Hospitals, In the United Kingdom, in a recent statement. “To see APL-2 maintain the same hematological benefits when dosing with Soliris was reduced in all and weaned entirely in three of four patients is impressive.”

“The data generated by APL-2 in treatment-naïve patients with PNH are impressive compared to our experience with Soliri,” added Peter Hillmen, MB ChB, PhD, professor of experimental hematology at the University of Leeds. “The early experience of APL-2 demonstrates that inhibiting C3 controls extravascular as well as intravascular hemolysis unlike inhibition of C5 where continued extravascular hemolysis is frequently problematic.”

To find out more, please click here.